Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
57 stopped studies mapped to Lymphoplasmacytic Lymphoma and descendants · 88% state a reason
Over the 57 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API ().
reasonMatches| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01962636 | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for… | N/A | terminated | Oct 14, 2013 | Masonic Cancer Center, University of Minnesota | No longer a research question to answer. | Other (stated, no rule matched) |
| NCT03246906 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity… | Phase 2 | terminated | Aug 11, 2017 | Fred Hutchinson Cancer Center | Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and… | Safety / toxicity |
| NCT03506373 | Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory… | Phase 2 | terminated | Apr 24, 2018 | Mayo Clinic | Discontinued after interim analysis for futility; no treatment successes observed in the first 12… | Efficacy / futility |
| NCT01198067 | Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom… | Phase 1 | terminated | Sep 9, 2010 | M.D. Anderson Cancer Center | \<75% participant accrual | Enrollment / accrual |
| NCT03333486 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell… | Phase 2 | terminated | Nov 7, 2017 | Roswell Park Cancer Institute | Futility analysis determined closure | Efficacy / futility |
| NCT02298816 | B-Cell Hematologic Malignancy Vaccination Registry(HMvax-Regist) | — | withdrawn | Nov 24, 2014 | Wake Forest University Health Sciences | No patients enrolled | Enrollment / accrual |
| NCT03225716 | A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4… | Phase 1 | terminated | Jul 21, 2017 | Dana-Farber Cancer Institute | Sponsor decision to end follow-up early | Sponsor / business decision |
| NCT04115059 | Dasatinib In Waldenström Macroglobulinemia | Phase 1 | terminated | Oct 3, 2019 | Jorge J. Castillo, MD | Lack of efficacy | Efficacy / futility |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | Phase 1 | terminated | Jan 16, 2013 | Stanford University | Planned Future Study | Other (stated, no rule matched) |
| NCT03679624 | Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia | Phase 2 | terminated | Sep 20, 2018 | Weill Medical College of Cornell University | Low accrual | Enrollment / accrual |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant… | Phase 2 | terminated | Jan 8, 2010 | University of Nebraska | Study was closed to accrual for safety related to the frequency of BK infections. | Safety / toxicity |
| NCT05176691 | HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL | Phase 1 | withdrawn | Jan 4, 2022 | Hutchmed | HUTCHMED has decided to discontinue the HMPL 760 study. | Other (stated, no rule matched) |
| NCT01416428 | Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic… | Phase 1 / Phase 2 | terminated | Aug 15, 2011 | Amgen | A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of… | Safety / toxicity |
| NCT04635683 | Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory… | Phase 1 | withdrawn | Nov 19, 2020 | Yazeed Sawalha | Investigational Drug removed from the market | Other (stated, no rule matched) |
| NCT04665115 | Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With… | Phase 2 | withdrawn | Dec 11, 2020 | Academic and Community Cancer Research United | Permanently closed 11/19/201. The widespread availability of COVID vaccination, the projected… | COVID-19 / pandemic |
| NCT01744912 | Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies | Phase 1 | terminated | Dec 7, 2012 | TG Therapeutics, Inc. | Sponsor's decision | Sponsor / business decision |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+… | Phase 1 / Phase 2 | terminated | Mar 5, 2013 | Northwestern University | Lack of funding | Funding |
| NCT00113802 | Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia | Phase 2 | terminated | Jun 13, 2005 | Gilead Sciences | low accrual | Enrollment / accrual |
| NCT01125293 | Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory… | Phase 1 / Phase 2 | terminated | May 18, 2010 | Dana-Farber Cancer Institute | Per protocol, Phase II is to be terminated early if a less than 5% of the Phase II participants… | Enrollment / accrual |
| NCT01678443 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With… | Phase 1 | terminated | Sep 5, 2012 | Fred Hutchinson Cancer Center | Terminated due to low accrual. | Enrollment / accrual |
| NCT03601819 | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | Phase 1 | terminated | Jul 26, 2018 | University of Michigan Rogel Cancer Center | Low accrual | Enrollment / accrual |
| NCT03037645 | Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers | Phase 1 / Phase 2 | terminated | Jan 31, 2017 | Sunesis Pharmaceuticals | Phase 1b portion completed. Sponsor decided not to proceed with P2 portion of study. Vecabrutinib… | Sponsor / business decision |
| NCT02991898 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | Phase 2 | terminated | Dec 14, 2016 | Masonic Cancer Center, University of Minnesota | Considering new technology for product. | Other (stated, no rule matched) |
| NCT04043845 | ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | Phase 1 | withdrawn | Aug 2, 2019 | Dana-Farber Cancer Institute | Business development reasons. | Sponsor / business decision |
| NCT03269552 | Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia… | Phase 2 | terminated | Aug 31, 2017 | University of Washington | Terminated due to low accrual. | Enrollment / accrual |
| NCT02092909 | Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's…(8400-401) | Phase 1 / Phase 2 | terminated | Mar 20, 2014 | Idera Pharmaceuticals, Inc. | Lack of efficacy | Efficacy / futility |
| NCT01408043 | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating… | N/A | terminated | Aug 3, 2011 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT00012298 | Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and… | Phase 1 / Phase 2 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Trial completed prematurely. | Other (stated, no rule matched) |
| NCT01779167 | Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom…(THRiL for WM) | Phase 2 | terminated | Jan 30, 2013 | Weill Medical College of Cornell University | Slow Accrual | Enrollment / accrual |
| NCT02168907 | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or… | Phase 1 | terminated | Jun 20, 2014 | Wake Forest University Health Sciences | Slow Accruals | Enrollment / accrual |
| NCT01812005 | Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory… | Phase 2 | terminated | Mar 15, 2013 | Ohio State University Comprehensive Cancer Center | Slow patient enrollment and study discontinued after 14 patients enrolled | Enrollment / accrual |
| NCT00003512 | Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's… | Phase 2 | withdrawn | Jan 27, 2003 | Burzynski Research Institute | No participants enrolled | Enrollment / accrual |
| NCT01163201 | T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in… | Phase 1 / Phase 2 | withdrawn | Jul 15, 2010 | Masonic Cancer Center, University of Minnesota | Replaced by a new study | Other (stated, no rule matched) |
| NCT01419795 | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed… | Phase 2 | terminated | Aug 18, 2011 | Fred Hutchinson Cancer Center | Low accrual | Enrollment / accrual |
| NCT00088881 | Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients… | Phase 2 | terminated | Aug 5, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02439138 | Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in… | Phase 2 | terminated | May 8, 2015 | Dana-Farber Cancer Institute | Safety issues from trials in CLL | Safety / toxicity |
| NCT02086591 | A Phase II Study of Doxycycline in Relapsed NHL | Phase 2 | terminated | Mar 13, 2014 | University of Rochester | Lack of accrual | Enrollment / accrual |
| NCT02281279 | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory… | Phase 1 / Phase 2 | withdrawn | Nov 3, 2014 | Mayo Clinic | not stated | Not stated |
| NCT00112723 | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | Phase 1 / Phase 2 | terminated | Jun 3, 2005 | National Cancer Institute (NCI) | Administratively Complete | Other (stated, no rule matched) |
| NCT01078974 | Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia | Phase 1 | terminated | Mar 2, 2010 | Steven P. Treon, MD, PhD | Safety concerns (IgM Flare) | Safety / toxicity |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With… | Phase 2 | withdrawn | Jul 27, 2012 | University of Medicine and Dentistry of New Jersey | Funding unavailable | Funding |
| NCT01536067 | Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom… | Phase 2 | terminated | Feb 20, 2012 | Roswell Park Cancer Institute | funding was withdrawn | Funding |
| NCT00142168 | CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia | Phase 2 | terminated | Sep 2, 2005 | Dana-Farber Cancer Institute | Toxicity | Safety / toxicity |
| NCT00575965 | Simvastatin in Waldenstrom's Macroglobulinemia | Phase 2 | terminated | Dec 18, 2007 | Dana-Farber Cancer Institute | Slow accrual led to early study termination. | Enrollment / accrual |
| NCT01045928 | Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell… | Phase 1 | terminated | Jan 11, 2010 | Case Comprehensive Cancer Center | Extreme toxicity in Phase I, study did not proceed to Phase II | Safety / toxicity |
| NCT02109224 | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With… | Phase 1 | terminated | Apr 9, 2014 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT01769911 | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With… | N/A | withdrawn | Jan 17, 2013 | Fred Hutchinson Cancer Center | not stated | Not stated |
| NCT00288067 | Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | terminated | Feb 7, 2006 | National Cancer Institute (NCI) | NCI stopped supplying fenretinide in November of 2012. | Other (stated, no rule matched) |
| NCT00089076 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | Phase 1 / Phase 2 | terminated | Aug 5, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00096005 | Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | Phase 1 | terminated | Nov 9, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated May 20, 2026source: clinicaltrials